XFOR - Latest News

X4 Pharmaceuticals, Inc. (XFOR), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $48.3M. Beta to the broader market is 0.32.

The article list below shows the most recent XFOR headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent XFOR Headlines

X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates

zacks.com - May 6, 2026

X4 Pharmaceuticals (XFOR) came out with a quarterly loss of $0. 16 per share versus the Zacks Consensus Estimate of a loss of $0.

X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

globenewswire.com - May 6, 2026

- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment by the end of Q3 2026 - - European Commission Approval of XOLREMDI® (

X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union

globenewswire.com - Apr 29, 2026

- European Commercialization will be Led by X4 Pharmaceuticals' Partner, Norgine -  - Global, Pivotal Phase 3 Clinical Trial Ongoing to Evaluate Mavor

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

globenewswire.com - Apr 1, 2026

BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology

X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates

zacks.com - Mar 17, 2026

X4 Pharmaceuticals (XFOR) came out with a quarterly loss of $0. 22 per share versus the Zacks Consensus Estimate of a loss of $0.

How News Affects XFOR Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track XFOR's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked XFOR news questions

What is the latest XFOR news headline?

The most recent XFOR headline (May 6, 2026) is "X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the XFOR news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What XFOR news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual XFOR options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.